Post-acute sequelae of COVID-19 — commonly called long COVID — has produced one of the most urgent modern search questions in medicine: what actually works. Hyperbaric oxygen therapy (HBOT) is one of the therapies most frequently discussed, sometimes overstated, and sometimes dismissed too quickly. The honest answer sits between the two extremes. The 2022 Tel Aviv randomized controlled trial offered the first reasonably rigorous human data on HBOT for post-COVID cognitive dysfunction. It is not a cure. It is a promising, replicable-looking signal that warrants clinical attention — particularly from medical-grade HBOT programs operating under physician supervision.
This article reviews what the evidence actually shows, what the proposed mechanisms are, the research protocol, its honest limits, and what a medical-grade long COVID HBOT program looks like at TrufaMED in Miami Beach.
A 2022 randomized controlled trial (Zilberman-Itskovich et al.) showed statistically significant cognitive, fatigue, and psychiatric improvements in long COVID patients after 40 HBOT sessions at 2.0 ATA over 8 weeks. Proposed mechanisms include mitochondrial support, reduced neuroinflammation, and endothelial repair. It is one promising data point — not a cure, not universally applicable, and currently off-label cash-pay. Medical-grade rigid monoplace chambers are required to approach the research pressures.
The most frequently cited human clinical trial on HBOT for long COVID is a 2022 publication in Scientific Reports by Zilberman-Itskovich and colleagues at Shamir Medical Center in Israel. The study enrolled 73 patients with post-COVID cognitive symptoms persisting at least three months after mild-to-moderate acute infection. They were randomized to 40 daily HBOT sessions at 2.0 ATA with 100% oxygen, or 40 sham sessions with ambient air at 1.03 ATA.
Outcomes were measured before treatment, after 40 sessions, and at follow-up. The HBOT arm showed statistically significant improvements across multiple domains: global cognitive function, attention, executive function, sleep, psychiatric symptoms, pain interference, and energy-fatigue measures. Some structural brain imaging changes were also reported in a subset of participants.
This is not a small pilot observational study. It is a randomized, sham-controlled trial published in a peer-reviewed journal with pre-specified endpoints. For a therapy that often attracts sweeping claims with minimal data, this is meaningful. It is also one trial, in one center, with one patient population. Clinicians should not extrapolate beyond what the data support, and patients should be told that honestly.
The biologic rationale for HBOT in long COVID draws from three mechanistic domains that each map to hypothesized drivers of post-viral syndromes.
Persistent fatigue and cognitive dysfunction in long COVID are thought to reflect, in part, acquired mitochondrial dysfunction. Cellular energy production is disrupted. HBOT drives dissolved oxygen into plasma well above what hemoglobin alone can carry (an application of Henry's Law), which appears in preclinical models to upregulate mitochondrial biogenesis, stabilize electron transport chain function, and activate hypoxia-adaptive pathways paradoxically triggered by hyperoxia-normoxia cycling.
A subset of long COVID patients display neuroinflammatory signatures on advanced imaging and in cerebrospinal fluid biomarkers. HBOT has documented anti-inflammatory effects — downregulating pro-inflammatory cytokines (TNF-alpha, IL-6) and upregulating anti-inflammatory mediators. This is a plausible pathway by which cognitive symptoms could improve.
COVID-19 is increasingly understood as an endothelial disease, with micro-clot formation and vascular dysfunction persisting well after acute infection. HBOT promotes angiogenesis and upregulates vascular endothelial growth factor (VEGF), which may contribute to repair of microvascular injury in long COVID.
These are mechanisms, not proofs. They are consistent with the observed clinical signal. They are not a guarantee that any individual patient will improve.
Understanding the research protocol matters because most real-world HBOT programs do not replicate it. The Tel Aviv study used:
No off-the-shelf soft-shell wellness chamber approaches 2.0 ATA. Soft chambers top out near 1.3 ATA, and none of the long COVID trial data applies to them. If someone is pursuing HBOT specifically for long COVID, the research points toward medical-grade rigid chambers at research-matching pressures.
This is why the distinction between medical-grade HBOT and mild HBOT matters so much in this conversation. For a deeper comparison, see mild HBOT vs medical-grade HBOT.
A single positive RCT is a signal. It is not a settled verdict. The honest limitations:
Anyone offering HBOT for long COVID without these caveats is either uninformed or selling something. Physician-led programs communicate this clearly up front.
At TrufaMED in Surfside, the long COVID HBOT pathway follows the published research protocol as closely as a clinical outpatient setting allows. The protocol is designed around three principles: physician-led screening, medical-grade chamber at research-matched pressures, and transparent expectations.
Before any HBOT session, patients meet with a board-certified physician — Dr. Uri Gedalia (CMO, board-certified general surgeon) or Dr. Shane D. Naidoo (Medical Director, board-certified emergency physician). The visit covers long COVID history, prior testing, current symptom burden, medication list, and any contraindications. Patients with untreated pneumothorax, recent otologic surgery, certain chemotherapy exposures, uncontrolled asthma, or specific cardiac conditions may need optimization before starting HBOT or may not be candidates. See our staff and credentials for physician backgrounds.
TrufaMED establishes a pre-treatment baseline against which to judge response. This typically includes validated cognitive screens, sleep and fatigue inventories, a patient-reported symptom burden scale, and any prior testing the patient has already completed.
A standard long COVID HBOT course at TrufaMED mirrors the Tel Aviv research — 90-minute sessions at 2.0 to 2.5 ATA in a rigid monoplace chamber, typically five days per week, with the goal of completing 40 sessions over 8 to 10 weeks. Exact pressure and session count are individualized by physician order.
Most long COVID HBOT patients at TrufaMED stack their protocol with IV nutrient therapy — often NAD+ for mitochondrial support, glutathione as an antioxidant, or Myers' Cocktail for micronutrient repletion. Every in-clinic IV session also includes complimentary red light therapy for mitochondrial photobiomodulation support.
At approximately session 20 and session 40, the physician re-evaluates the patient against baseline. Protocol may be extended if the response curve is still improving. If the response is flat by mid-course and the patient has been compliant, honest conversation about next steps replaces open-ended session accumulation.
Long COVID is not an FDA-approved HBOT indication, which means insurance will not cover sessions used for this indication. HBOT is cash-pay for this use case. Session pricing, package pricing, and concierge membership integration are detailed at HBOT cost in Miami Beach.
For patients considering the full 40-session protocol, TrufaMED offers physician-coordinated package rates. Concierge members receive integrated HBOT access within the membership structure along with physician coordination across all therapeutic domains.
| Approach | Evidence Base | Typical Course | Cost Profile |
|---|---|---|---|
| Medical-grade HBOT | One RCT (Tel Aviv 2022), plausible mechanisms | 40 sessions over 8 weeks | Cash-pay, moderate-to-high |
| Pulmonary rehabilitation | Supported for breathlessness, exercise tolerance | 6–12 weeks, structured | Often insurance-covered |
| Cognitive rehabilitation | Supported for post-concussive and post-viral cognitive symptoms | Weekly sessions, 3–6 months | Variable insurance coverage |
| Autonomic rehabilitation (for POTS features) | Supported in subsets | Progressive, months | Variable |
| Mild HBOT (soft chambers, ≤1.3 ATA) | No specific long COVID RCT evidence | Variable | Lower per-session, weak rationale |
HBOT does not replace any of these other modalities. In many long COVID patients, the optimal plan is layered — physician-led rehabilitation, appropriate specialty referrals, and HBOT as an adjunct where clinically reasonable.
TrufaMED is Florida's only Joint Commission-accredited urgent care, a standard normally applied to hospital emergency departments. For a therapy with specific pressure requirements, staff training demands, and emergency protocols (including fire-safety protocols unique to high-FiO2 environments), that accreditation is not decoration.
TrufaMED operates a rigid monoplace chamber rated for medical-grade pressures up to 2.5 ATA — matching the research protocol. Every HBOT patient is cleared by a board-certified physician before initiating treatment. Sessions are monitored by trained staff. Red light therapy and IV therapy are available in the same clinic, under the same physician oversight. For full HBOT benefits detail, see HBOT benefits explained.
Surfside is directly adjacent to Miami Beach, Bal Harbour, Sunny Isles, and Aventura. Parking is on-site. Hours are Mon-Fri 9 AM-9 PM, Saturday 11 AM-11 PM, Sunday 12 PM-8 PM — giving long-course patients flexibility to fit 40 sessions into real life.
You have likely read mixed coverage on HBOT and long COVID. The honest take: one reasonably rigorous human RCT, plausible mechanisms, real limitations, and a cash-pay indication delivered inside a medical-grade program. If that framing aligns with how you process clinical information, TrufaMED's long COVID HBOT protocol may be worth a physician clearance visit. If you need a guaranteed outcome or insurance coverage, this is not the indication for you.
For related reading, see HBOT recovery for athletes and HBOT and red light therapy. For general urgent care or testing needs unrelated to HBOT, see TrufaMED urgent care and testing services.
Every TrufaMED HBOT patient starts with a board-certified physician screening visit — no exceptions. This is the safest and most evidence-aligned path to a long COVID HBOT protocol in Miami Beach.
Contact Our TeamNo. HBOT is not a cure for long COVID, and anyone claiming otherwise is overstating the evidence. The 2022 randomized controlled trial out of Tel Aviv (Zilberman-Itskovich et al., Scientific Reports) showed statistically significant improvement in cognitive function, fatigue, pain, sleep, and psychiatric symptoms in patients with post-COVID cognitive deficits who completed 40 sessions at 2.0 ATA. It is one promising, reasonably rigorous data point. More replication studies are needed.
The published research protocol ran 40 sessions, five days per week, for eight weeks. Each session was 90 minutes at 2.0 ATA breathing 100% oxygen with short air breaks. Shorter protocols have not been tested in rigorous trials for this indication.
No. Long COVID is currently an off-label, cash-pay indication for HBOT in the United States. FDA-cleared indications include air embolism, carbon monoxide poisoning, diabetic foot ulcers meeting specific criteria, osteoradionecrosis, and delayed radiation injury, among others. Insurance will not cover HBOT for long COVID.
Medical-grade rigid monoplace chambers deliver 100% oxygen at 2.0 to 2.5 ATA — the pressures used in the Tel Aviv long COVID research. Soft-shell mild HBOT chambers reach approximately 1.3 ATA with ambient air enriched oxygen. No credible long COVID trial has shown benefit at mild HBOT pressures. If pursuing HBOT for long COVID, seek a medical-grade chamber.
Patients with untreated pneumothorax, certain chemotherapy exposures, recent ear or sinus surgery, uncontrolled asthma, and some cardiac conditions. A physician-led clearance visit identifies contraindications before any session. TrufaMED requires physician screening before enrolling any HBOT patient.
In the published research, statistically meaningful symptom changes were measured after completing the full 40-session course. Anecdotal subjective improvements — sleep quality, mental clarity — are commonly reported by the 10 to 15 session mark, but a fair evaluation requires the full protocol.
Each session runs approximately 90 minutes inside a rigid monoplace chamber. Patients breathe 100% medical-grade oxygen at a physician-prescribed pressure between 2.0 and 2.5 ATA. Staff monitor the entire session. Patients typically read, watch a screen through the clear acrylic, or rest. There is nothing to do during treatment other than follow pressurization and depressurization cadence.
Yes. Many patients choose to stack HBOT with IV nutrient therapy on the same day — typically the IV first, then HBOT. NAD+, glutathione, and Myers' Cocktail IVs are common complements. The physician-led protocol determines sequencing based on individual goals and clinical picture.
HBOT in a medical-grade chamber is generally well tolerated. The most common adverse events are middle ear barotrauma (managed with equalization technique), transient claustrophobia (manageable in a monoplace with clear walls and staff nearby), and rare oxygen toxicity (mitigated by air breaks and physician-set pressure limits). Joint Commission accreditation requires TrufaMED to maintain documented safety, emergency, and staff training protocols.
A list of current medications, a recent primary-care or specialist note documenting long COVID symptoms, and any prior imaging or testing results. A TrufaMED physician will review everything in the initial clearance visit and design a session schedule with you.
TrufaMED Urgent Care and Concierge Medicine, 9445 Harding Avenue, Surfside, FL 33154 — directly adjacent to Miami Beach. Joint Commission accredited. Open Mon-Fri 9 AM-9 PM, Sat 11 AM-11 PM, Sun 12 PM-8 PM. Board-certified physicians on shift every day. See our team and explore our concierge program.
Serving These Areas
Copyright © 2026 TrufaMED Urgent Care
